Department of Surgical Sciences, Oral Medicine Section, CIR-Dental School, University of Turin.
Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, University of Turin.
J Oral Sci. 2021;63(3):217-226. doi: 10.2334/josnusd.21-0016.
A systematic review was carried out to identify if periprocedural administration of systemic antibiotics could decrease risk of medication-related osteonecrosis of the jaws (MRONJ) in patients under antiresorptive and/or biologic agents for teeth extraction. PubMed/MEDLINE and Scopus were systematically searched for case-series with more than 10 patients, retrospective/prospective studies, and trials concerning this issue. Manual searching of references from previous reviews was also carried out. Of 1,512 results, 17 studies were included, focusing on antibiotics for extraction in patients under intravenous bisphosphonates (8 studies), oral bisphosphonates (2 studies), oral and intravenous bisphosphonates (6 studies), and denosumab (1 study), of which 12 performed dental extraction with surgical flap. With no trials found, "quality in prognosis studies" (QUIPS) tool was used to evaluate risk of bias. First-line treatment was 2-3 grams of oral amoxicillin in 76.4% of studies; 300-600 mg of clindamycin was the alternative treatment in 23.5% of studies. Treatment ranged from 3 to 20 days, consisting of 6-7 days in 47% of studies. No microbiologic insight was provided. A significantly higher risk of MRONJ for patients unexposed to antibiotics was provided in one retrospective study. QUIPS tool revealed moderate-high risk of bias. With empirical data from bias-carrying, heterogeneous observational studies, the validity of antibiotics is yet to be established.
一项系统评价旨在确定在接受抗吸收剂和/或生物制剂进行牙齿拔除的患者中,围手术期全身性抗生素的应用是否可以降低与药物相关的颌骨坏死(MRONJ)的风险。通过系统检索 PubMed/MEDLINE 和 Scopus,以查找涉及该问题的超过 10 例患者的病例系列、回顾性/前瞻性研究和试验。还对手册搜索了以前综述的参考文献。在 1512 个结果中,纳入了 17 项研究,这些研究集中在静脉内双膦酸盐(8 项研究)、口服双膦酸盐(2 项研究)、口服和静脉内双膦酸盐(6 项研究)和地舒单抗(1 项研究)患者拔牙时使用的抗生素,其中 12 项研究使用手术瓣进行拔牙。由于未发现试验,因此使用“预后研究质量”(QUIPS)工具评估偏倚风险。在 76.4%的研究中,一线治疗是 2-3 克口服阿莫西林;在 23.5%的研究中,替代治疗是 300-600 毫克克林霉素。治疗时间从 3 到 20 天不等,47%的研究中治疗时间为 6-7 天。没有提供微生物学见解。一项回顾性研究表明,未接受抗生素治疗的患者发生 MRONJ 的风险显著更高。QUIPS 工具显示出中度至高度偏倚风险。由于存在偏倚和异质性观察研究的经验数据,抗生素的有效性仍有待确定。